The ability of biomarkers to assess the severity of atopic dermatitis

Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Takeshi Nakahara, MD, PhD [verfasserIn] Daisuke Onozuka, PhD [verfasserIn] Satoshi Nunomura, PhD [verfasserIn] Hidehisa Saeki, MD, PhD [verfasserIn] Motoi Takenaka, MD, PhD [verfasserIn] Mai Matsumoto, MD, PhD [verfasserIn] Yoko Kataoka, MD [verfasserIn] Rai Fujimoto, MD, PhD [verfasserIn] Sakae Kaneko, MD, PhD [verfasserIn] Eishin Morita, MD, PhD [verfasserIn] Akio Tanaka, MD, PhD [verfasserIn] Ryo Saito, MD, PhD [verfasserIn] Tatsuro Okano, MD, PhD [verfasserIn] Tomomitsu Miyagaki, MD, PhD [verfasserIn] Natsuko Aoki, MD, PhD [verfasserIn] Kimiko Nakajima, MD, PhD [verfasserIn] Susumu Ichiyama, MD, PhD [verfasserIn] Makiko Kido-Nakahara, MD, PhD [verfasserIn] Kyoko Tonomura, MD, PhD [verfasserIn] Yukinobu Nakagawa, MD, PhD [verfasserIn] Risa Tamagawa-Mineoka, MD, PhD [verfasserIn] Koji Masuda, MD, PhD [verfasserIn] Takuya Takeichi, MD, PhD [verfasserIn] Masashi Akiyama, MD, PhD [verfasserIn] Yozo Ishiuji, MD, PhD [verfasserIn] Michie Katsuta, MD, PhD [verfasserIn] Yuki Kinoshita, MD, PhD [verfasserIn] Chiharu Tateishi, MD, PhD [verfasserIn] Aya Yamamoto, MD, PhD [verfasserIn] Akimichi Morita, MD, PhD [verfasserIn] Haruna Matsuda-Hirose, MD, PhD [verfasserIn] Yutaka Hatano, MD, PhD [verfasserIn] Hiroshi Kawasaki, MD, PhD [verfasserIn] Ayano Fukushima-Nomura, MD [verfasserIn] Mamitaro Ohtsuki, MD, PhD [verfasserIn] Koji Kamiya, MD, PhD [verfasserIn] Yudai Kabata, MD, PhD [verfasserIn] Riichiro Abe, MD, PhD [verfasserIn] Hiroshi Mitsui, MD, PhD [verfasserIn] Tatsuyoshi Kawamura, MD, PhD [verfasserIn] Gaku Tsuji, MD, PhD [verfasserIn] Norito Katoh, MD, PhD [verfasserIn] Masutaka Furue, MD, PhD [verfasserIn] Kenji Izuhara, MD, PhD [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2024

Schlagwörter:	Atopic dermatitis biomarker B-PAD Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab EASI eotaxin-3

Übergeordnetes Werk:	In: Journal of Allergy and Clinical Immunology: Global - Elsevier, 2023, 3(2024), 1, Seite 100175-
Übergeordnetes Werk:	volume:3 ; year:2024 ; number:1 ; pages:100175-

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1016/j.jacig.2023.100175

Katalog-ID:	DOAJ093770073

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ093770073
003	DE-627
005	20240414161517.0
007	cr uuu---uuuuu
008	240413s2024 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.jacig.2023.100175 \|2 doi
035			\|a (DE-627)DOAJ093770073
035			\|a (DE-599)DOAJe11f03b3ae004428bb4cca14383d8c63
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC581-607
100	0		\|a Takeshi Nakahara, MD, PhD \|e verfasserin \|4 aut
245	1	4	\|a The ability of biomarkers to assess the severity of atopic dermatitis
264		1	\|c 2024
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD.
650		4	\|a Atopic dermatitis
650		4	\|a biomarker
650		4	\|a B-PAD
650		4	\|a Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab
650		4	\|a EASI
650		4	\|a eotaxin-3
653		0	\|a Immunologic diseases. Allergy
700	0		\|a Daisuke Onozuka, PhD \|e verfasserin \|4 aut
700	0		\|a Satoshi Nunomura, PhD \|e verfasserin \|4 aut
700	0		\|a Hidehisa Saeki, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Motoi Takenaka, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Mai Matsumoto, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Yoko Kataoka, MD \|e verfasserin \|4 aut
700	0		\|a Rai Fujimoto, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Sakae Kaneko, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Eishin Morita, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Akio Tanaka, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Ryo Saito, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Tatsuro Okano, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Tomomitsu Miyagaki, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Natsuko Aoki, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Kimiko Nakajima, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Susumu Ichiyama, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Makiko Kido-Nakahara, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Kyoko Tonomura, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Yukinobu Nakagawa, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Risa Tamagawa-Mineoka, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Koji Masuda, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Takuya Takeichi, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Masashi Akiyama, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Yozo Ishiuji, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Michie Katsuta, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Yuki Kinoshita, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Chiharu Tateishi, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Aya Yamamoto, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Akimichi Morita, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Haruna Matsuda-Hirose, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Yutaka Hatano, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Hiroshi Kawasaki, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Ayano Fukushima-Nomura, MD \|e verfasserin \|4 aut
700	0		\|a Mamitaro Ohtsuki, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Koji Kamiya, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Yudai Kabata, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Riichiro Abe, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Hiroshi Mitsui, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Tatsuyoshi Kawamura, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Gaku Tsuji, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Norito Katoh, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Masutaka Furue, MD, PhD \|e verfasserin \|4 aut
700	0		\|a Kenji Izuhara, MD, PhD \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Allergy and Clinical Immunology: Global \|d Elsevier, 2023 \|g 3(2024), 1, Seite 100175- \|w (DE-627)1786549182 \|w (DE-600)3106741-4 \|x 27728293 \|7 nnns
773	1	8	\|g volume:3 \|g year:2024 \|g number:1 \|g pages:100175-
856	4	0	\|u https://doi.org/10.1016/j.jacig.2023.100175 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/e11f03b3ae004428bb4cca14383d8c63 \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S2772829323001005 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2772-8293 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 3 \|j 2024 \|e 1 \|h 100175-

Indexfelder

author_variant	n m p t nmp nmpt o p d op opd n p s np nps s m p h smp smph t m p m tmp tmpm m m p m mmp mmpm k m y km kmy f m p r fmp fmpr k m p s kmp kmps m m p e mmp mmpe t m p a tmp tmpa s m p r smp smpr o m p t omp ompt m m p t mmp mmpt a m p n amp ampn n m p k nmp nmpk i m p s imp imps k n m p m knmp knmpm t m p k tmp tmpk n m p y nmp nmpy t m m p r tmmp tmmpr m m p k mmp mmpk t m p t tmp tmpt a m p m amp ampm i m p y imp impy k m p m kmp kmpm k m p y kmp kmpy t m p c tmp tmpc y m p a ymp ympa m m p a mmp mmpa m h m p h mhmp mhmph h m p y hmp hmpy k m p h kmp kmph f n m a fnm fnma o m p m omp ompm k m p k kmp kmpk k m p y kmp kmpy a m p r amp ampr m m p h mmp mmph k m p t kmp kmpt t m p g tmp tmpg k m p n kmp kmpn f m p m fmp fmpm i m p k imp impk
matchkey_str	article:27728293:2024----::haiiyfimresoseshsvrto
hierarchy_sort_str	2024
callnumber-subject-code	RC
publishDate	2024
allfields	10.1016/j.jacig.2023.100175 doi (DE-627)DOAJ093770073 (DE-599)DOAJe11f03b3ae004428bb4cca14383d8c63 DE-627 ger DE-627 rakwb eng RC581-607 Takeshi Nakahara, MD, PhD verfasserin aut The ability of biomarkers to assess the severity of atopic dermatitis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD. Atopic dermatitis biomarker B-PAD Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab EASI eotaxin-3 Immunologic diseases. Allergy Daisuke Onozuka, PhD verfasserin aut Satoshi Nunomura, PhD verfasserin aut Hidehisa Saeki, MD, PhD verfasserin aut Motoi Takenaka, MD, PhD verfasserin aut Mai Matsumoto, MD, PhD verfasserin aut Yoko Kataoka, MD verfasserin aut Rai Fujimoto, MD, PhD verfasserin aut Sakae Kaneko, MD, PhD verfasserin aut Eishin Morita, MD, PhD verfasserin aut Akio Tanaka, MD, PhD verfasserin aut Ryo Saito, MD, PhD verfasserin aut Tatsuro Okano, MD, PhD verfasserin aut Tomomitsu Miyagaki, MD, PhD verfasserin aut Natsuko Aoki, MD, PhD verfasserin aut Kimiko Nakajima, MD, PhD verfasserin aut Susumu Ichiyama, MD, PhD verfasserin aut Makiko Kido-Nakahara, MD, PhD verfasserin aut Kyoko Tonomura, MD, PhD verfasserin aut Yukinobu Nakagawa, MD, PhD verfasserin aut Risa Tamagawa-Mineoka, MD, PhD verfasserin aut Koji Masuda, MD, PhD verfasserin aut Takuya Takeichi, MD, PhD verfasserin aut Masashi Akiyama, MD, PhD verfasserin aut Yozo Ishiuji, MD, PhD verfasserin aut Michie Katsuta, MD, PhD verfasserin aut Yuki Kinoshita, MD, PhD verfasserin aut Chiharu Tateishi, MD, PhD verfasserin aut Aya Yamamoto, MD, PhD verfasserin aut Akimichi Morita, MD, PhD verfasserin aut Haruna Matsuda-Hirose, MD, PhD verfasserin aut Yutaka Hatano, MD, PhD verfasserin aut Hiroshi Kawasaki, MD, PhD verfasserin aut Ayano Fukushima-Nomura, MD verfasserin aut Mamitaro Ohtsuki, MD, PhD verfasserin aut Koji Kamiya, MD, PhD verfasserin aut Yudai Kabata, MD, PhD verfasserin aut Riichiro Abe, MD, PhD verfasserin aut Hiroshi Mitsui, MD, PhD verfasserin aut Tatsuyoshi Kawamura, MD, PhD verfasserin aut Gaku Tsuji, MD, PhD verfasserin aut Norito Katoh, MD, PhD verfasserin aut Masutaka Furue, MD, PhD verfasserin aut Kenji Izuhara, MD, PhD verfasserin aut In Journal of Allergy and Clinical Immunology: Global Elsevier, 2023 3(2024), 1, Seite 100175- (DE-627)1786549182 (DE-600)3106741-4 27728293 nnns volume:3 year:2024 number:1 pages:100175- https://doi.org/10.1016/j.jacig.2023.100175 kostenfrei https://doaj.org/article/e11f03b3ae004428bb4cca14383d8c63 kostenfrei http://www.sciencedirect.com/science/article/pii/S2772829323001005 kostenfrei https://doaj.org/toc/2772-8293 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 3 2024 1 100175-
spelling	10.1016/j.jacig.2023.100175 doi (DE-627)DOAJ093770073 (DE-599)DOAJe11f03b3ae004428bb4cca14383d8c63 DE-627 ger DE-627 rakwb eng RC581-607 Takeshi Nakahara, MD, PhD verfasserin aut The ability of biomarkers to assess the severity of atopic dermatitis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD. Atopic dermatitis biomarker B-PAD Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab EASI eotaxin-3 Immunologic diseases. Allergy Daisuke Onozuka, PhD verfasserin aut Satoshi Nunomura, PhD verfasserin aut Hidehisa Saeki, MD, PhD verfasserin aut Motoi Takenaka, MD, PhD verfasserin aut Mai Matsumoto, MD, PhD verfasserin aut Yoko Kataoka, MD verfasserin aut Rai Fujimoto, MD, PhD verfasserin aut Sakae Kaneko, MD, PhD verfasserin aut Eishin Morita, MD, PhD verfasserin aut Akio Tanaka, MD, PhD verfasserin aut Ryo Saito, MD, PhD verfasserin aut Tatsuro Okano, MD, PhD verfasserin aut Tomomitsu Miyagaki, MD, PhD verfasserin aut Natsuko Aoki, MD, PhD verfasserin aut Kimiko Nakajima, MD, PhD verfasserin aut Susumu Ichiyama, MD, PhD verfasserin aut Makiko Kido-Nakahara, MD, PhD verfasserin aut Kyoko Tonomura, MD, PhD verfasserin aut Yukinobu Nakagawa, MD, PhD verfasserin aut Risa Tamagawa-Mineoka, MD, PhD verfasserin aut Koji Masuda, MD, PhD verfasserin aut Takuya Takeichi, MD, PhD verfasserin aut Masashi Akiyama, MD, PhD verfasserin aut Yozo Ishiuji, MD, PhD verfasserin aut Michie Katsuta, MD, PhD verfasserin aut Yuki Kinoshita, MD, PhD verfasserin aut Chiharu Tateishi, MD, PhD verfasserin aut Aya Yamamoto, MD, PhD verfasserin aut Akimichi Morita, MD, PhD verfasserin aut Haruna Matsuda-Hirose, MD, PhD verfasserin aut Yutaka Hatano, MD, PhD verfasserin aut Hiroshi Kawasaki, MD, PhD verfasserin aut Ayano Fukushima-Nomura, MD verfasserin aut Mamitaro Ohtsuki, MD, PhD verfasserin aut Koji Kamiya, MD, PhD verfasserin aut Yudai Kabata, MD, PhD verfasserin aut Riichiro Abe, MD, PhD verfasserin aut Hiroshi Mitsui, MD, PhD verfasserin aut Tatsuyoshi Kawamura, MD, PhD verfasserin aut Gaku Tsuji, MD, PhD verfasserin aut Norito Katoh, MD, PhD verfasserin aut Masutaka Furue, MD, PhD verfasserin aut Kenji Izuhara, MD, PhD verfasserin aut In Journal of Allergy and Clinical Immunology: Global Elsevier, 2023 3(2024), 1, Seite 100175- (DE-627)1786549182 (DE-600)3106741-4 27728293 nnns volume:3 year:2024 number:1 pages:100175- https://doi.org/10.1016/j.jacig.2023.100175 kostenfrei https://doaj.org/article/e11f03b3ae004428bb4cca14383d8c63 kostenfrei http://www.sciencedirect.com/science/article/pii/S2772829323001005 kostenfrei https://doaj.org/toc/2772-8293 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 3 2024 1 100175-
allfields_unstemmed	10.1016/j.jacig.2023.100175 doi (DE-627)DOAJ093770073 (DE-599)DOAJe11f03b3ae004428bb4cca14383d8c63 DE-627 ger DE-627 rakwb eng RC581-607 Takeshi Nakahara, MD, PhD verfasserin aut The ability of biomarkers to assess the severity of atopic dermatitis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD. Atopic dermatitis biomarker B-PAD Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab EASI eotaxin-3 Immunologic diseases. Allergy Daisuke Onozuka, PhD verfasserin aut Satoshi Nunomura, PhD verfasserin aut Hidehisa Saeki, MD, PhD verfasserin aut Motoi Takenaka, MD, PhD verfasserin aut Mai Matsumoto, MD, PhD verfasserin aut Yoko Kataoka, MD verfasserin aut Rai Fujimoto, MD, PhD verfasserin aut Sakae Kaneko, MD, PhD verfasserin aut Eishin Morita, MD, PhD verfasserin aut Akio Tanaka, MD, PhD verfasserin aut Ryo Saito, MD, PhD verfasserin aut Tatsuro Okano, MD, PhD verfasserin aut Tomomitsu Miyagaki, MD, PhD verfasserin aut Natsuko Aoki, MD, PhD verfasserin aut Kimiko Nakajima, MD, PhD verfasserin aut Susumu Ichiyama, MD, PhD verfasserin aut Makiko Kido-Nakahara, MD, PhD verfasserin aut Kyoko Tonomura, MD, PhD verfasserin aut Yukinobu Nakagawa, MD, PhD verfasserin aut Risa Tamagawa-Mineoka, MD, PhD verfasserin aut Koji Masuda, MD, PhD verfasserin aut Takuya Takeichi, MD, PhD verfasserin aut Masashi Akiyama, MD, PhD verfasserin aut Yozo Ishiuji, MD, PhD verfasserin aut Michie Katsuta, MD, PhD verfasserin aut Yuki Kinoshita, MD, PhD verfasserin aut Chiharu Tateishi, MD, PhD verfasserin aut Aya Yamamoto, MD, PhD verfasserin aut Akimichi Morita, MD, PhD verfasserin aut Haruna Matsuda-Hirose, MD, PhD verfasserin aut Yutaka Hatano, MD, PhD verfasserin aut Hiroshi Kawasaki, MD, PhD verfasserin aut Ayano Fukushima-Nomura, MD verfasserin aut Mamitaro Ohtsuki, MD, PhD verfasserin aut Koji Kamiya, MD, PhD verfasserin aut Yudai Kabata, MD, PhD verfasserin aut Riichiro Abe, MD, PhD verfasserin aut Hiroshi Mitsui, MD, PhD verfasserin aut Tatsuyoshi Kawamura, MD, PhD verfasserin aut Gaku Tsuji, MD, PhD verfasserin aut Norito Katoh, MD, PhD verfasserin aut Masutaka Furue, MD, PhD verfasserin aut Kenji Izuhara, MD, PhD verfasserin aut In Journal of Allergy and Clinical Immunology: Global Elsevier, 2023 3(2024), 1, Seite 100175- (DE-627)1786549182 (DE-600)3106741-4 27728293 nnns volume:3 year:2024 number:1 pages:100175- https://doi.org/10.1016/j.jacig.2023.100175 kostenfrei https://doaj.org/article/e11f03b3ae004428bb4cca14383d8c63 kostenfrei http://www.sciencedirect.com/science/article/pii/S2772829323001005 kostenfrei https://doaj.org/toc/2772-8293 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 3 2024 1 100175-
allfieldsGer	10.1016/j.jacig.2023.100175 doi (DE-627)DOAJ093770073 (DE-599)DOAJe11f03b3ae004428bb4cca14383d8c63 DE-627 ger DE-627 rakwb eng RC581-607 Takeshi Nakahara, MD, PhD verfasserin aut The ability of biomarkers to assess the severity of atopic dermatitis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD. Atopic dermatitis biomarker B-PAD Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab EASI eotaxin-3 Immunologic diseases. Allergy Daisuke Onozuka, PhD verfasserin aut Satoshi Nunomura, PhD verfasserin aut Hidehisa Saeki, MD, PhD verfasserin aut Motoi Takenaka, MD, PhD verfasserin aut Mai Matsumoto, MD, PhD verfasserin aut Yoko Kataoka, MD verfasserin aut Rai Fujimoto, MD, PhD verfasserin aut Sakae Kaneko, MD, PhD verfasserin aut Eishin Morita, MD, PhD verfasserin aut Akio Tanaka, MD, PhD verfasserin aut Ryo Saito, MD, PhD verfasserin aut Tatsuro Okano, MD, PhD verfasserin aut Tomomitsu Miyagaki, MD, PhD verfasserin aut Natsuko Aoki, MD, PhD verfasserin aut Kimiko Nakajima, MD, PhD verfasserin aut Susumu Ichiyama, MD, PhD verfasserin aut Makiko Kido-Nakahara, MD, PhD verfasserin aut Kyoko Tonomura, MD, PhD verfasserin aut Yukinobu Nakagawa, MD, PhD verfasserin aut Risa Tamagawa-Mineoka, MD, PhD verfasserin aut Koji Masuda, MD, PhD verfasserin aut Takuya Takeichi, MD, PhD verfasserin aut Masashi Akiyama, MD, PhD verfasserin aut Yozo Ishiuji, MD, PhD verfasserin aut Michie Katsuta, MD, PhD verfasserin aut Yuki Kinoshita, MD, PhD verfasserin aut Chiharu Tateishi, MD, PhD verfasserin aut Aya Yamamoto, MD, PhD verfasserin aut Akimichi Morita, MD, PhD verfasserin aut Haruna Matsuda-Hirose, MD, PhD verfasserin aut Yutaka Hatano, MD, PhD verfasserin aut Hiroshi Kawasaki, MD, PhD verfasserin aut Ayano Fukushima-Nomura, MD verfasserin aut Mamitaro Ohtsuki, MD, PhD verfasserin aut Koji Kamiya, MD, PhD verfasserin aut Yudai Kabata, MD, PhD verfasserin aut Riichiro Abe, MD, PhD verfasserin aut Hiroshi Mitsui, MD, PhD verfasserin aut Tatsuyoshi Kawamura, MD, PhD verfasserin aut Gaku Tsuji, MD, PhD verfasserin aut Norito Katoh, MD, PhD verfasserin aut Masutaka Furue, MD, PhD verfasserin aut Kenji Izuhara, MD, PhD verfasserin aut In Journal of Allergy and Clinical Immunology: Global Elsevier, 2023 3(2024), 1, Seite 100175- (DE-627)1786549182 (DE-600)3106741-4 27728293 nnns volume:3 year:2024 number:1 pages:100175- https://doi.org/10.1016/j.jacig.2023.100175 kostenfrei https://doaj.org/article/e11f03b3ae004428bb4cca14383d8c63 kostenfrei http://www.sciencedirect.com/science/article/pii/S2772829323001005 kostenfrei https://doaj.org/toc/2772-8293 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 3 2024 1 100175-
allfieldsSound	10.1016/j.jacig.2023.100175 doi (DE-627)DOAJ093770073 (DE-599)DOAJe11f03b3ae004428bb4cca14383d8c63 DE-627 ger DE-627 rakwb eng RC581-607 Takeshi Nakahara, MD, PhD verfasserin aut The ability of biomarkers to assess the severity of atopic dermatitis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD. Atopic dermatitis biomarker B-PAD Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab EASI eotaxin-3 Immunologic diseases. Allergy Daisuke Onozuka, PhD verfasserin aut Satoshi Nunomura, PhD verfasserin aut Hidehisa Saeki, MD, PhD verfasserin aut Motoi Takenaka, MD, PhD verfasserin aut Mai Matsumoto, MD, PhD verfasserin aut Yoko Kataoka, MD verfasserin aut Rai Fujimoto, MD, PhD verfasserin aut Sakae Kaneko, MD, PhD verfasserin aut Eishin Morita, MD, PhD verfasserin aut Akio Tanaka, MD, PhD verfasserin aut Ryo Saito, MD, PhD verfasserin aut Tatsuro Okano, MD, PhD verfasserin aut Tomomitsu Miyagaki, MD, PhD verfasserin aut Natsuko Aoki, MD, PhD verfasserin aut Kimiko Nakajima, MD, PhD verfasserin aut Susumu Ichiyama, MD, PhD verfasserin aut Makiko Kido-Nakahara, MD, PhD verfasserin aut Kyoko Tonomura, MD, PhD verfasserin aut Yukinobu Nakagawa, MD, PhD verfasserin aut Risa Tamagawa-Mineoka, MD, PhD verfasserin aut Koji Masuda, MD, PhD verfasserin aut Takuya Takeichi, MD, PhD verfasserin aut Masashi Akiyama, MD, PhD verfasserin aut Yozo Ishiuji, MD, PhD verfasserin aut Michie Katsuta, MD, PhD verfasserin aut Yuki Kinoshita, MD, PhD verfasserin aut Chiharu Tateishi, MD, PhD verfasserin aut Aya Yamamoto, MD, PhD verfasserin aut Akimichi Morita, MD, PhD verfasserin aut Haruna Matsuda-Hirose, MD, PhD verfasserin aut Yutaka Hatano, MD, PhD verfasserin aut Hiroshi Kawasaki, MD, PhD verfasserin aut Ayano Fukushima-Nomura, MD verfasserin aut Mamitaro Ohtsuki, MD, PhD verfasserin aut Koji Kamiya, MD, PhD verfasserin aut Yudai Kabata, MD, PhD verfasserin aut Riichiro Abe, MD, PhD verfasserin aut Hiroshi Mitsui, MD, PhD verfasserin aut Tatsuyoshi Kawamura, MD, PhD verfasserin aut Gaku Tsuji, MD, PhD verfasserin aut Norito Katoh, MD, PhD verfasserin aut Masutaka Furue, MD, PhD verfasserin aut Kenji Izuhara, MD, PhD verfasserin aut In Journal of Allergy and Clinical Immunology: Global Elsevier, 2023 3(2024), 1, Seite 100175- (DE-627)1786549182 (DE-600)3106741-4 27728293 nnns volume:3 year:2024 number:1 pages:100175- https://doi.org/10.1016/j.jacig.2023.100175 kostenfrei https://doaj.org/article/e11f03b3ae004428bb4cca14383d8c63 kostenfrei http://www.sciencedirect.com/science/article/pii/S2772829323001005 kostenfrei https://doaj.org/toc/2772-8293 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 3 2024 1 100175-
language	English
source	In Journal of Allergy and Clinical Immunology: Global 3(2024), 1, Seite 100175- volume:3 year:2024 number:1 pages:100175-
sourceStr	In Journal of Allergy and Clinical Immunology: Global 3(2024), 1, Seite 100175- volume:3 year:2024 number:1 pages:100175-
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Atopic dermatitis biomarker B-PAD Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab EASI eotaxin-3 Immunologic diseases. Allergy
isfreeaccess_bool	true
container_title	Journal of Allergy and Clinical Immunology: Global
authorswithroles_txt_mv	Takeshi Nakahara, MD, PhD @@aut@@ Daisuke Onozuka, PhD @@aut@@ Satoshi Nunomura, PhD @@aut@@ Hidehisa Saeki, MD, PhD @@aut@@ Motoi Takenaka, MD, PhD @@aut@@ Mai Matsumoto, MD, PhD @@aut@@ Yoko Kataoka, MD @@aut@@ Rai Fujimoto, MD, PhD @@aut@@ Sakae Kaneko, MD, PhD @@aut@@ Eishin Morita, MD, PhD @@aut@@ Akio Tanaka, MD, PhD @@aut@@ Ryo Saito, MD, PhD @@aut@@ Tatsuro Okano, MD, PhD @@aut@@ Tomomitsu Miyagaki, MD, PhD @@aut@@ Natsuko Aoki, MD, PhD @@aut@@ Kimiko Nakajima, MD, PhD @@aut@@ Susumu Ichiyama, MD, PhD @@aut@@ Makiko Kido-Nakahara, MD, PhD @@aut@@ Kyoko Tonomura, MD, PhD @@aut@@ Yukinobu Nakagawa, MD, PhD @@aut@@ Risa Tamagawa-Mineoka, MD, PhD @@aut@@ Koji Masuda, MD, PhD @@aut@@ Takuya Takeichi, MD, PhD @@aut@@ Masashi Akiyama, MD, PhD @@aut@@ Yozo Ishiuji, MD, PhD @@aut@@ Michie Katsuta, MD, PhD @@aut@@ Yuki Kinoshita, MD, PhD @@aut@@ Chiharu Tateishi, MD, PhD @@aut@@ Aya Yamamoto, MD, PhD @@aut@@ Akimichi Morita, MD, PhD @@aut@@ Haruna Matsuda-Hirose, MD, PhD @@aut@@ Yutaka Hatano, MD, PhD @@aut@@ Hiroshi Kawasaki, MD, PhD @@aut@@ Ayano Fukushima-Nomura, MD @@aut@@ Mamitaro Ohtsuki, MD, PhD @@aut@@ Koji Kamiya, MD, PhD @@aut@@ Yudai Kabata, MD, PhD @@aut@@ Riichiro Abe, MD, PhD @@aut@@ Hiroshi Mitsui, MD, PhD @@aut@@ Tatsuyoshi Kawamura, MD, PhD @@aut@@ Gaku Tsuji, MD, PhD @@aut@@ Norito Katoh, MD, PhD @@aut@@ Masutaka Furue, MD, PhD @@aut@@ Kenji Izuhara, MD, PhD @@aut@@
publishDateDaySort_date	2024-01-01T00:00:00Z
hierarchy_top_id	1786549182
id	DOAJ093770073
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ093770073</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414161517.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jacig.2023.100175</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ093770073</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe11f03b3ae004428bb4cca14383d8c63</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Takeshi Nakahara, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The ability of biomarkers to assess the severity of atopic dermatitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Atopic dermatitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biomarker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">B-PAD</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">EASI</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">eotaxin-3</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daisuke Onozuka, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Satoshi Nunomura, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hidehisa Saeki, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Motoi Takenaka, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mai Matsumoto, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoko Kataoka, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rai Fujimoto, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sakae Kaneko, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eishin Morita, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Akio Tanaka, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ryo Saito, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tatsuro Okano, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomomitsu Miyagaki, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natsuko Aoki, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kimiko Nakajima, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Susumu Ichiyama, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Makiko Kido-Nakahara, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kyoko Tonomura, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yukinobu Nakagawa, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Risa Tamagawa-Mineoka, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koji Masuda, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takuya Takeichi, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masashi Akiyama, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yozo Ishiuji, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michie Katsuta, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuki Kinoshita, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiharu Tateishi, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aya Yamamoto, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Akimichi Morita, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Haruna Matsuda-Hirose, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yutaka Hatano, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Kawasaki, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ayano Fukushima-Nomura, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mamitaro Ohtsuki, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koji Kamiya, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yudai Kabata, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Riichiro Abe, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Mitsui, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tatsuyoshi Kawamura, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gaku Tsuji, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Norito Katoh, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masutaka Furue, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kenji Izuhara, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Allergy and Clinical Immunology: Global</subfield><subfield code="d">Elsevier, 2023</subfield><subfield code="g">3(2024), 1, Seite 100175-</subfield><subfield code="w">(DE-627)1786549182</subfield><subfield code="w">(DE-600)3106741-4</subfield><subfield code="x">27728293</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:100175-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jacig.2023.100175</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e11f03b3ae004428bb4cca14383d8c63</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2772829323001005</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2772-8293</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2024</subfield><subfield code="e">1</subfield><subfield code="h">100175-</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Takeshi Nakahara, MD, PhD
spellingShingle	Takeshi Nakahara, MD, PhD misc RC581-607 misc Atopic dermatitis misc biomarker misc B-PAD misc Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab misc EASI misc eotaxin-3 misc Immunologic diseases. Allergy The ability of biomarkers to assess the severity of atopic dermatitis
authorStr	Takeshi Nakahara, MD, PhD
ppnlink_with_tag_str_mv	@@773@@(DE-627)1786549182
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC581-607
illustrated	Not Illustrated
issn	27728293
topic_title	RC581-607 The ability of biomarkers to assess the severity of atopic dermatitis Atopic dermatitis biomarker B-PAD Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab EASI eotaxin-3
topic	misc RC581-607 misc Atopic dermatitis misc biomarker misc B-PAD misc Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab misc EASI misc eotaxin-3 misc Immunologic diseases. Allergy
topic_unstemmed	misc RC581-607 misc Atopic dermatitis misc biomarker misc B-PAD misc Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab misc EASI misc eotaxin-3 misc Immunologic diseases. Allergy
topic_browse	misc RC581-607 misc Atopic dermatitis misc biomarker misc B-PAD misc Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab misc EASI misc eotaxin-3 misc Immunologic diseases. Allergy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Allergy and Clinical Immunology: Global
hierarchy_parent_id	1786549182
hierarchy_top_title	Journal of Allergy and Clinical Immunology: Global
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1786549182 (DE-600)3106741-4
title	The ability of biomarkers to assess the severity of atopic dermatitis
ctrlnum	(DE-627)DOAJ093770073 (DE-599)DOAJe11f03b3ae004428bb4cca14383d8c63
title_full	The ability of biomarkers to assess the severity of atopic dermatitis
author_sort	Takeshi Nakahara, MD, PhD
journal	Journal of Allergy and Clinical Immunology: Global
journalStr	Journal of Allergy and Clinical Immunology: Global
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2024
contenttype_str_mv	txt
container_start_page	100175
author_browse	Takeshi Nakahara, MD, PhD Daisuke Onozuka, PhD Satoshi Nunomura, PhD Hidehisa Saeki, MD, PhD Motoi Takenaka, MD, PhD Mai Matsumoto, MD, PhD Yoko Kataoka, MD Rai Fujimoto, MD, PhD Sakae Kaneko, MD, PhD Eishin Morita, MD, PhD Akio Tanaka, MD, PhD Ryo Saito, MD, PhD Tatsuro Okano, MD, PhD Tomomitsu Miyagaki, MD, PhD Natsuko Aoki, MD, PhD Kimiko Nakajima, MD, PhD Susumu Ichiyama, MD, PhD Makiko Kido-Nakahara, MD, PhD Kyoko Tonomura, MD, PhD Yukinobu Nakagawa, MD, PhD Risa Tamagawa-Mineoka, MD, PhD Koji Masuda, MD, PhD Takuya Takeichi, MD, PhD Masashi Akiyama, MD, PhD Yozo Ishiuji, MD, PhD Michie Katsuta, MD, PhD Yuki Kinoshita, MD, PhD Chiharu Tateishi, MD, PhD Aya Yamamoto, MD, PhD Akimichi Morita, MD, PhD Haruna Matsuda-Hirose, MD, PhD Yutaka Hatano, MD, PhD Hiroshi Kawasaki, MD, PhD Ayano Fukushima-Nomura, MD Mamitaro Ohtsuki, MD, PhD Koji Kamiya, MD, PhD Yudai Kabata, MD, PhD Riichiro Abe, MD, PhD Hiroshi Mitsui, MD, PhD Tatsuyoshi Kawamura, MD, PhD Gaku Tsuji, MD, PhD Norito Katoh, MD, PhD Masutaka Furue, MD, PhD Kenji Izuhara, MD, PhD
container_volume	3
class	RC581-607
format_se	Elektronische Aufsätze
author-letter	Takeshi Nakahara, MD, PhD
doi_str_mv	10.1016/j.jacig.2023.100175
author2-role	verfasserin
title_sort	ability of biomarkers to assess the severity of atopic dermatitis
callnumber	RC581-607
title_auth	The ability of biomarkers to assess the severity of atopic dermatitis
abstract	Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD.
abstractGer	Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD.
abstract_unstemmed	Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700
container_issue	1
title_short	The ability of biomarkers to assess the severity of atopic dermatitis
url	https://doi.org/10.1016/j.jacig.2023.100175 https://doaj.org/article/e11f03b3ae004428bb4cca14383d8c63 http://www.sciencedirect.com/science/article/pii/S2772829323001005 https://doaj.org/toc/2772-8293
remote_bool	true
author2	Daisuke Onozuka, PhD Satoshi Nunomura, PhD Hidehisa Saeki, MD, PhD Motoi Takenaka, MD, PhD Mai Matsumoto, MD, PhD Yoko Kataoka, MD Rai Fujimoto, MD, PhD Sakae Kaneko, MD, PhD Eishin Morita, MD, PhD Akio Tanaka, MD, PhD Ryo Saito, MD, PhD Tatsuro Okano, MD, PhD Tomomitsu Miyagaki, MD, PhD Natsuko Aoki, MD, PhD Kimiko Nakajima, MD, PhD Susumu Ichiyama, MD, PhD Makiko Kido-Nakahara, MD, PhD Kyoko Tonomura, MD, PhD Yukinobu Nakagawa, MD, PhD Risa Tamagawa-Mineoka, MD, PhD Koji Masuda, MD, PhD Takuya Takeichi, MD, PhD Masashi Akiyama, MD, PhD Yozo Ishiuji, MD, PhD Michie Katsuta, MD, PhD Yuki Kinoshita, MD, PhD Chiharu Tateishi, MD, PhD Aya Yamamoto, MD, PhD Akimichi Morita, MD, PhD Haruna Matsuda-Hirose, MD, PhD Yutaka Hatano, MD, PhD Hiroshi Kawasaki, MD, PhD Ayano Fukushima-Nomura, MD Mamitaro Ohtsuki, MD, PhD Koji Kamiya, MD, PhD Yudai Kabata, MD, PhD Riichiro Abe, MD, PhD Hiroshi Mitsui, MD, PhD Tatsuyoshi Kawamura, MD, PhD Gaku Tsuji, MD, PhD Norito Katoh, MD, PhD Masutaka Furue, MD, PhD Kenji Izuhara, MD, PhD
author2Str	Daisuke Onozuka, PhD Satoshi Nunomura, PhD Hidehisa Saeki, MD, PhD Motoi Takenaka, MD, PhD Mai Matsumoto, MD, PhD Yoko Kataoka, MD Rai Fujimoto, MD, PhD Sakae Kaneko, MD, PhD Eishin Morita, MD, PhD Akio Tanaka, MD, PhD Ryo Saito, MD, PhD Tatsuro Okano, MD, PhD Tomomitsu Miyagaki, MD, PhD Natsuko Aoki, MD, PhD Kimiko Nakajima, MD, PhD Susumu Ichiyama, MD, PhD Makiko Kido-Nakahara, MD, PhD Kyoko Tonomura, MD, PhD Yukinobu Nakagawa, MD, PhD Risa Tamagawa-Mineoka, MD, PhD Koji Masuda, MD, PhD Takuya Takeichi, MD, PhD Masashi Akiyama, MD, PhD Yozo Ishiuji, MD, PhD Michie Katsuta, MD, PhD Yuki Kinoshita, MD, PhD Chiharu Tateishi, MD, PhD Aya Yamamoto, MD, PhD Akimichi Morita, MD, PhD Haruna Matsuda-Hirose, MD, PhD Yutaka Hatano, MD, PhD Hiroshi Kawasaki, MD, PhD Ayano Fukushima-Nomura, MD Mamitaro Ohtsuki, MD, PhD Koji Kamiya, MD, PhD Yudai Kabata, MD, PhD Riichiro Abe, MD, PhD Hiroshi Mitsui, MD, PhD Tatsuyoshi Kawamura, MD, PhD Gaku Tsuji, MD, PhD Norito Katoh, MD, PhD Masutaka Furue, MD, PhD Kenji Izuhara, MD, PhD
ppnlink	1786549182
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1016/j.jacig.2023.100175
callnumber-a	RC581-607
up_date	2024-07-03T19:18:09.751Z
_version_	1803586675415187456
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ093770073</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414161517.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jacig.2023.100175</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ093770073</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe11f03b3ae004428bb4cca14383d8c63</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Takeshi Nakahara, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The ability of biomarkers to assess the severity of atopic dermatitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Atopic dermatitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biomarker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">B-PAD</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">EASI</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">eotaxin-3</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daisuke Onozuka, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Satoshi Nunomura, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hidehisa Saeki, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Motoi Takenaka, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mai Matsumoto, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoko Kataoka, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rai Fujimoto, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sakae Kaneko, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eishin Morita, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Akio Tanaka, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ryo Saito, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tatsuro Okano, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomomitsu Miyagaki, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natsuko Aoki, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kimiko Nakajima, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Susumu Ichiyama, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Makiko Kido-Nakahara, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kyoko Tonomura, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yukinobu Nakagawa, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Risa Tamagawa-Mineoka, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koji Masuda, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takuya Takeichi, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masashi Akiyama, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yozo Ishiuji, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michie Katsuta, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuki Kinoshita, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiharu Tateishi, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aya Yamamoto, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Akimichi Morita, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Haruna Matsuda-Hirose, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yutaka Hatano, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Kawasaki, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ayano Fukushima-Nomura, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mamitaro Ohtsuki, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koji Kamiya, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yudai Kabata, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Riichiro Abe, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Mitsui, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tatsuyoshi Kawamura, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gaku Tsuji, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Norito Katoh, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masutaka Furue, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kenji Izuhara, MD, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Allergy and Clinical Immunology: Global</subfield><subfield code="d">Elsevier, 2023</subfield><subfield code="g">3(2024), 1, Seite 100175-</subfield><subfield code="w">(DE-627)1786549182</subfield><subfield code="w">(DE-600)3106741-4</subfield><subfield code="x">27728293</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:100175-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jacig.2023.100175</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e11f03b3ae004428bb4cca14383d8c63</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2772829323001005</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2772-8293</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2024</subfield><subfield code="e">1</subfield><subfield code="h">100175-</subfield></datafield></record></collection>
score	7.4001083

Nicht das Richtige dabei?

Schreiben Sie uns!

The ability of biomarkers to assess the severity of atopic dermatitis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?